Historical record - last NADAC effective date: 5/17/2017
Product Information
ABILIFY 5 MG TABLET is a brand product labeled by Otsuka America Pharmaceutical Inc., priced at $28.4389 per EA under NDC 59148000735. Its NADAC has been published 214 times since Nov 28, 2013.
FDA first approved this application on Nov 15, 2002. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the ARIPIPRAZOLE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
5 mg/1
Manufacturer
Otsuka America Pharmaceutical Inc.NDC
59148000735
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
5/17/2017
Active Ingredients
ARIPIPRAZOLEApproval Type
New Drug (NDA)
FDA Application
NDA021436FDA Approved
11/15/2002
TE Code
AB
On Market Since
11/15/2002
Pharmacological Classes
Price Statistics
The NADAC for ABILIFY 5 MG TABLET has been published 214 times since Nov 28, 2013, and over the history we have for it it has risen 29.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $28.4389 per EA |
|---|---|
| All-time high | $28.9020 (Aug 10, 2016) |
| All-time low | $21.9977 (Nov 28, 2013) |
| Median price | $28.6608 |
| Average price | $27.6289 |
| Largest weekly change | +16.0% (Jan 8, 2014) |
| Weeks tracked | 214 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
+29.3%
Last surveyed Dec 27, 2017 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of ABILIFY 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ABILIFY 5 MG TABLET, manufactured by Otsuka America Pharmaceutical Inc., is $28.4389 per EA (NDC 59148000735), effective Dec 27, 2017.
How has the price of ABILIFY 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for ABILIFY 5 MG TABLET has risen 29.3%. It has been tracked across 214 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ABILIFY 5 MG TABLET?
Since Nov 28, 2013, the NADAC for ABILIFY 5 MG TABLET has ranged from a low of $21.9977 (Nov 28, 2013) to a high of $28.9020 (Aug 10, 2016), with a median of $28.6608 per EA.
Are there cheaper alternatives to ABILIFY 5 MG TABLET?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ARIPIPRAZOLE 5 MG TABLET, is $0.1059 per EA — about 99% below ABILIFY 5 MG TABLET.
Who manufactures ABILIFY 5 MG TABLET?
ABILIFY 5 MG TABLET (NDC 59148000735) is labeled by Otsuka America Pharmaceutical Inc., and CMS classifies it as a brand product.